Effects of Nicotine on Areas of Impaired and Preserved Functioning in Schizophrenia
| Status: | Completed |
|---|---|
| Conditions: | Schizophrenia, Smoking Cessation, Tobacco Consumers |
| Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 4/17/2018 |
| Start Date: | June 2, 2009 |
| End Date: | June 11, 2013 |
Background:
- Some people with schizophrenia have problems with their working memory and paying
attention for extended periods. These difficulties cannot be treated with antipsychotic
medications or with many standard therapies.
- The prevalence of cigarette smoking among individuals with schizophrenia is about three
times higher than in the general population. Research has shown that nicotine, the
addictive component found in cigarettes, can help improve attentional and working memory
performance. Researchers are interested in learning more about whether there may be an
overlap in the cognitive functions beneficially affected by nicotine and areas of
dysfunction in individuals with schizophrenia.
Objectives:
- To evaluate the potential of transdermal nicotine to alleviate cognitive deficits in
schizophrenia, and to determine whether naturally maintained cigarette-smoking, in
comparison, is an effective self-medication.
- To gather preliminary data on genetics that may account for individual and group
differences in the performance effects of nicotine.
Eligibility:
- Current smokers (25 or more cigarettes per week for at least 1 year) between 18 and 55
years of age who are either healthy volunteers or have been diagnosed with
schizophrenia/schizoaffective disorder.
Design:
- The study will require five visits to the research center, with an initial screening
visit, a training session, and three test sessions. Ideally, all visits will occur 1
week apart.
- Training session: Participants will receive training on the types of computerized
cognitive and attentional behavior tests that will be given during the active portion of
the study. Participants will also fill out questionnaires on nicotine use and other
alcohol and drug use.
- Test sessions: Participants will be assigned to random groups and will complete tests
that assess cognitive performance (a) while maintaining their usual smoking behavior,
(b) after minimal deprivation (3.5 hours without smoking) while wearing a placebo patch,
and (c) under the influence of a standard nicotine patch. The order of these sessions
will be different for individual participants.
- Participants will provide blood samples throughout the research study for evaluation
purposes.
- Some people with schizophrenia have problems with their working memory and paying
attention for extended periods. These difficulties cannot be treated with antipsychotic
medications or with many standard therapies.
- The prevalence of cigarette smoking among individuals with schizophrenia is about three
times higher than in the general population. Research has shown that nicotine, the
addictive component found in cigarettes, can help improve attentional and working memory
performance. Researchers are interested in learning more about whether there may be an
overlap in the cognitive functions beneficially affected by nicotine and areas of
dysfunction in individuals with schizophrenia.
Objectives:
- To evaluate the potential of transdermal nicotine to alleviate cognitive deficits in
schizophrenia, and to determine whether naturally maintained cigarette-smoking, in
comparison, is an effective self-medication.
- To gather preliminary data on genetics that may account for individual and group
differences in the performance effects of nicotine.
Eligibility:
- Current smokers (25 or more cigarettes per week for at least 1 year) between 18 and 55
years of age who are either healthy volunteers or have been diagnosed with
schizophrenia/schizoaffective disorder.
Design:
- The study will require five visits to the research center, with an initial screening
visit, a training session, and three test sessions. Ideally, all visits will occur 1
week apart.
- Training session: Participants will receive training on the types of computerized
cognitive and attentional behavior tests that will be given during the active portion of
the study. Participants will also fill out questionnaires on nicotine use and other
alcohol and drug use.
- Test sessions: Participants will be assigned to random groups and will complete tests
that assess cognitive performance (a) while maintaining their usual smoking behavior,
(b) after minimal deprivation (3.5 hours without smoking) while wearing a placebo patch,
and (c) under the influence of a standard nicotine patch. The order of these sessions
will be different for individual participants.
- Participants will provide blood samples throughout the research study for evaluation
purposes.
Objective:
1. To evaluate the potential of transdermal nicotine to alleviate distinct cognitive
deficits in schizophrenia, and to determine whether naturally maintained
cigarette-smoking, in comparison, is an effective self-medication.
2. To gather preliminary data on genotypes that may account for interindividual and group
differences in the performance effects of nicotine.
Study population:
45 regular smokers with schizophrenia, 45 matched control smokers (greater than or equal to 5
cigarettes/day).
Design:
Double-blind, placebo-controlled, within-subject study, evaluating cognitive functions under
conditions of normal smoking, transdermal nicotine (14 mg/day), and placebo (minimal tobacco
deprivation).
Outcome measures:
Measures of cognitive task performance, measures of subjective state, plasma concentrations
of nicotine and metabolites, and genotype with regards to genes coding for nicotinic receptor
subunits, MAO, and COMT.
1. To evaluate the potential of transdermal nicotine to alleviate distinct cognitive
deficits in schizophrenia, and to determine whether naturally maintained
cigarette-smoking, in comparison, is an effective self-medication.
2. To gather preliminary data on genotypes that may account for interindividual and group
differences in the performance effects of nicotine.
Study population:
45 regular smokers with schizophrenia, 45 matched control smokers (greater than or equal to 5
cigarettes/day).
Design:
Double-blind, placebo-controlled, within-subject study, evaluating cognitive functions under
conditions of normal smoking, transdermal nicotine (14 mg/day), and placebo (minimal tobacco
deprivation).
Outcome measures:
Measures of cognitive task performance, measures of subjective state, plasma concentrations
of nicotine and metabolites, and genotype with regards to genes coding for nicotinic receptor
subunits, MAO, and COMT.
- INCLUSION CRITERIA:
All participants:
1. Age 18 through 55. The aim is to minimize population inhomogeneity related to
cognitive decline due to normal aging.
2. Smoker of 5 or more cigarettes, cigarillos or cigars per day, on 5 or more days/week,
for at least the last 12 months
3. Normal or corrected to normal visual acuity (at least 20/100).
Participants with mental illness, additional inclusion criteria:
1. DSM-IV diagnosis of schizophrenia or schizoaffective disorder
2. Ability to give written informed consent
3. Four weeks of stable pharmacological treatment (same psychiatric medication at same
dose)
EXCLUSION CRITERIA:
All participants:
1. History of myocardial infarction, heart failure, angina, stroke or severe arrhythmias,
EKG abnormalities as specified under Screening methods
2. Uncontrolled high blood pressure (resting systolic above 150 or diastolic above 90 mm
Hg)
3. Neurological conditions such as stroke, seizures, dementia or organic brain syndrome
4. Any condition likely to impair cognitive function such as mental retardation,
attention deficit disorder or severe pharmacological sedation
5. Treatment for tobacco dependence in the last four months
6. Alcohol or substance abuse or dependence other than nicotine within the last 12 months
7. Pregnancy, verified by urine pregnancy test for females at first visit and in the
beginning of each of the two patch administration sessions
8. Lactating
Healthy controls, additional exclusion criterion:
9. Current psychiatric Axis I disorder or Axis II schizophrenia spectrum disorder,
verified by Structured Clinical Interview for DSM-IV (SCID)
Participants with mental illness, additional exclusion criterion:
10. Treated with benztropine (a nicotinic and muscarinic antagonist) or with an
acetylcholine esterase inhibitor currently or within the last four weeks
We found this trial at
1
site
Click here to add this to my saved trials
